|Articles|November 15, 2002

BioPharm International

  • BioPharm International-11-01-2002
  • Volume 15
  • Issue 11

Survival Guide to FDA Inspections: Part 3, Responding to Observations

by Massoud Lavian and Paul W. Allen, Clarkston Consulting
To view a PDF of this article from the BioPharm International archives, click this link

Articles in this issue

about 23 years ago

Outsourcing Outlook: Will CROs find opportunity in a Reinvigorated European R&D Sector?

about 23 years ago

Inside Washington: Major Changes Ahead for FDA

about 23 years ago

Bioinformatics Databases ? Questions of Copyright

about 23 years ago

European Editor's Report ? An Industry Comes of Age

about 23 years ago

Guest Editorial: Back to the Beginning

about 23 years ago

Employing Near-Infrared Spectroscopic Methods of Analysis for Fermentation Monitoring and Control: Part 1, Method Development

about 23 years ago

You Have Failed . . . A Case Study in Warning Letter Remediation

about 23 years ago

Analytical Advances: The Protein ID Autobahn ? Automated Nanoelectrospray Mass Spectrometry

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!